Read about breakthrough science, the everyday people who make it happen, and the patients we serve.
Minimal residual disease (MRD) could be a powerful way to evaluate new treatments for blood cancer. But how do we get MRD to reach its full potential as an endpoint in clinical trials?
Genentech Cancer Genome Project scientists are helping uncover the hidden genetic drivers of cancer. Learn more about these important findings.
Tell us what you think about our company, products, or website.
Science is a way of thinking much more than it is a body of knowledge.